| Business Summary | | Cambridge
Heart,
Inc.
is
engaged
in
the
research,
development
and
commercialization
of
products
for
the
non-invasive
diagnosis
of
cardiac
disease.
The
Company
is
addressing
such
key
problems
in
cardiac
diagnosis
as
the
identification
of
those
at
risk
of
sudden
cardiac
arrest
and
the
early
detection
of
coronary
artery
disease.
Its
proprietary
technology,
Microvolt
T-Wave
Alternans
is
the
only
diagnostic
tool
cleared
by
the
U.S.
Food
and
Drug
Administration
to
non-invasively
measure
Microvolt
levels
of
T-Wave
Alternans,
an
extremely
subtle
beat-to-beat
fluctuation
in
a
patient's
heartbeat.
The
Company's
CH
2000
Alternans
System
(CH
2000),
Heartwave
System
and
Heartwave
EP
System,
and
Micro-V
Alternans
Sensors
have
all
received
510(k)
clearance
from
the
FDA
for
sale
in
the
United
States.
Its
CH
2000
and
Micro-V
Alternans
Sensors
have
received
the
CE
mark
for
sale
in
Europe
and
have
been
approved
for
sale
by
the
Ministry
of
Health
in
Japan. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cambridge
Heart,
Inc.
is
engaged
in
the
research,
development
and
commercialization
of
products
for
the
non-invasive
diagnosis
of
cardiac
disease.
For
the
three
months
ended
3/31/01,
revenues
increased
64%
to
$678
thousand.
Net
loss
decreased
18%
to
$1.7
million.
Revenues
reflect
increased
sales
of
Microvolt
T-Wave
Alternan
products.
Net
loss
was
partially
offset
by
increased
S/G/A
expenses
due
to
the
expansion
of
the
U.S.
sales
organization. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
739;
after
tax
earnings
were
-1,702. (Preliminary; reported in thousands of dollars.) | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Jeffrey Arnold, 51 Chairman | $312K | David Chazanovitz, 50 Pres,
CEO, Chief Operating Officer | -- | Robert Palardy, 52 CFO,
VP of Fin. and Admin. | 154K | James Sheppard, 41 VP
of Operations | 142K | Eric Dufford, 42 VP
of Sales and Marketing and Sec. | 182K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|